Ups and downs of Kasauli CRI: Despite challenges, the institute can again reach its prime with adequate budget and timely upgrade
Ups and downs of Kasauli CRI: Despite challenges, the institute can again reach its prime with adequate budget and timely upgrade is drawing significant interest across the industry.
Once the only Central undertaking manufacturing life-saving vaccines, the Himachal institute had its licence revoked for not meeting WHO norms in 2008. Its recent rollout of an indigenously developed vaccine shows its potential, and limitations.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Net-Zero Energy Buildings Market to Reach US$ 198.1 Billion by 2033 as Sustainable Construction and Renewable Integration Accelerate
- Schroders to Maintain Non-US HQ in London Following Nuveen Deal
- AI pioneer Li's World Labs raises $1 billion in funding
- Meta could end up owning 10% of AMD in new chip deal
Source: Original →